151 related articles for article (PubMed ID: 38279837)
21. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
22. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
23. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients.
Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC
Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497
[TBL] [Abstract][Full Text] [Related]
24. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
25. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
[TBL] [Abstract][Full Text] [Related]
26. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience.
Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E
Front Immunol; 2022; 13():1049188. PubMed ID: 36505469
[TBL] [Abstract][Full Text] [Related]
27. Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study.
Iavarone M; Tosetti G; Facchetti F; Topa M; Er JM; Hang SK; Licari D; Lombardi A; D'Ambrosio R; Degasperi E; Loglio A; Oggioni C; Perbellini R; Caccia R; Bandera A; Gori A; Ceriotti F; Scudeller L; Bertoletti A; Lampertico P
Dig Liver Dis; 2023 Feb; 55(2):160-168. PubMed ID: 36266209
[TBL] [Abstract][Full Text] [Related]
28. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
[TBL] [Abstract][Full Text] [Related]
29. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
[TBL] [Abstract][Full Text] [Related]
30. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
[TBL] [Abstract][Full Text] [Related]
31. Humoral and T-cell-mediated immunity to SARS-CoV-2 vaccination in patients with liver disease and transplant recipients.
Willauer AN; Rouster SD; Meeds HL; Jennings CL; Abdel-Hameed EA; Daria DE; Stambrook EP; Shata MTM; Sherman KE
Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36930861
[TBL] [Abstract][Full Text] [Related]
32. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
33. The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy.
Alshami A; Bahbah H; Al Attas R; Aldokhi F; Azzam A
Pediatr Transplant; 2024 May; 28(3):e14712. PubMed ID: 38553800
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS-CoV-2 vaccine and Ad5-nCoV booster in pediatric liver transplant recipients.
Zheng Z; Wu H; Sun X; Lu Y; Song Y; Luo Y; Zhou T; Feng M; Wan P; Zhu J; Shen N; Cao Q; Liang J; Xia Q; Xue F
J Med Virol; 2024 Mar; 96(3):e29543. PubMed ID: 38528839
[TBL] [Abstract][Full Text] [Related]
35. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
[TBL] [Abstract][Full Text] [Related]
36. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
37. Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19.
Kirchner T; Heinrich S; Bonifacius A; Engel B; Ruhl L; Pink I; Thomas N; Martens J; Hoeper MM; Blasczyk R; Wedemeyer H; Jaeckel E; Li Y; Falk CS; Eiz-Vesper B; Taubert R
PLoS One; 2022; 17(11):e0276929. PubMed ID: 36322587
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
39. Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021-2022.
Perrig L; Abela IA; Banholzer N; Audigé A; Epp S; Mugglin C; Zürcher K; Egger M; Trkola A; Fenner L
Swiss Med Wkly; 2023 Dec; 153():3502. PubMed ID: 38579325
[TBL] [Abstract][Full Text] [Related]
40. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
Front Immunol; 2022; 13():1050211. PubMed ID: 36532067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]